Substantial Depletion of Vicine, Levodopa, and Tyramine in a Fava Bean Protein-Based Nutritional Product
Author(s) -
Paul W. Johns,
Steven R. Hertzler
Publication year - 2021
Publication title -
international journal of food science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.479
H-Index - 18
eISSN - 2356-7015
pISSN - 2314-5765
DOI - 10.1155/2021/6669544
Subject(s) - tyramine , chemistry , levodopa , biochemistry , pharmacology , medicine , disease , parkinson's disease
A commercial fava bean protein isolate and a liquid nutritional product formulated with it were tested by validated HPLC methods for the favism-associated pyrimidine glycoside vicine, the dopamine precursor levodopa, and the biogenic amine tyramine. The vicine, levodopa, and tyramine concentrations in the protein isolate—306, 13.3, and <0.5 mg/kg, respectively—when expressed on a protein basis—34, 1.5, and <0.06 mg/100 g protein, respectively—were at least 96% lower than the vicine, levodopa, and tyramine (protein-based) concentrations reported for fava beans (≥900, ~200, and ~4 mg/100 g protein, respectively). This was also true for the vicine (13 mg/kg or 22 mg/100 g protein), levodopa (≤0.17 mg/kg or ≤0.3 mg/100 g protein), and tyramine (0.08 mg/kg or 0.14 mg/100 g protein) concentrations in the nutritional product. On the basis of these data, one serving (11 fl. oz.) of the nutritional product would deliver approximately 5 mg of vicine, <1 mg of levodopa, and <0.1 mg of tyramine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom